experimental group:Tilelizumab combined with Anlotinib

2 trials

Sponsors

Peking Union Medical College Hospital, Yanbian University Hospital

Conditions

None small cell lung cancerUrothelial carcinoma

Early Phase 1

A phase II clinical study of tislelizumab combined with anlotinib in the treatment of non-squamous NSCLC with EGFR sensitive mutation and failure of previous EGFR TKI therapy

RecruitingChiCTR2100044773

Peking Union Medical College HospitalNone small cell lung cancer

Start: 2021-03-22Updated: 2021-10-26

Phase 2

Tirelizumab combined with amlotinib for second-line treatment of advanced urothelial carcinoma II Phase II clinical study

RecruitingChiCTR2100045112

Yanbian University HospitalUrothelial carcinoma

Start: 2021-04-01Updated: 2021-11-08